ITGAV and breast carcinoma: For example, SVIL is intricately involved in tumour angiogenesis in liver cancer [43], whilst ITGAV silencing has proven to inhibit the cell proliferation and invasion of breast cancer cell lines [44] and CDH5 has been demonstrated as a biomarker of metastatic breast cancer [45].